Abstract
IntroductionSodium-glucose cotransporter 2 (SGLT2) inhibitors are known to reduce the risk of cardiovascular events in patients with type 2 diabetes (T2DM). The recent ground-breaking DAPA-HF trial has shown similar results...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
